Business
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date,
About this update from Vericel Corporation
[{"type":"text","content":" Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Total net revenue of $52.6 millionMACI® net revenue growth of 15% to $46.3 millionBurn Care net revenue of $6.3 million, consisting of $5.0 million of Epicel® revenue and $1.3 million of NexoBrid® revenueGross margin of 69%Net loss of $11.2 million, or $0.23 per diluted shareNon-GAAP adjusted EBITDA of $3.2 millionOperating cash flow of $6.6 millionAs of March 31, 2025, the Company had approximately $162 million in cash, restricted cash and investments, and no debt Business Highlights and Updates Record first quarter MACI revenue and total revenueSecond highest number of MACI biopsies and surgeons taking biopsies in a quarter since launch, with second highest number of biopsies in any month since launch in MarchApproximately 400 MACI Arthro™ surgeons trained to date, with year-to-date biopsy growth over 30% for trained surgeonsNexoBrid first quarter revenue increased 207% versus the prior year and 31% versus the prior quarterHighest number of Epicel biopsies in a quarter since 2023 in the first quarterStrong start for Epicel in the second quarter with graft volume from cases completed or scheduled to date exceeding total graft volume in the first quarterOn track to initiate MACI Ankle™ clinical study in the second half of 2025The Company anticipates that tariffs on foreign goods imported into the U.S. will have minimal impact on its business and operations, and that the impact of current or future tariffs on its cost of goods sold and gross margin in 2025 and 2026 will be negligible “The Company is off to a solid start to the year, with record first quarter MACI revenue and total Company reven...